Eli Lilly and Company will invest $15 million in MiNA Therapeutics following an earlier agreement to use MiNA’s small activating RNA technology to develop drug candidates for immuno-oncology and genetic diseases. MiNA will use the cash to expand its drug pipeline. /business/Business-Roundup/99/i25 20210709 Concentrates 99 25 /magazine/99/09925.html Business Roundup Business con bus business Business Roundup Chemical & Engineering News Business Roundup Business Roundup
July 09, 2021
Bennink left Organon soon thereafter to form his own company, Pantarhei Bioscience, which launched studies on estetrol in women’s health and oncology applications. In 2009 the company formed a contraceptive-focused joint venture with Mithra; by 2015, Mithra had acquired full rights to estetrol for contraceptive and menopausal uses. Pantarhei continues to develop the molecule for oncology and veterinary use. Mithra had picked Cambridge Major Laboratories’ ChemShop unit in Weert, the Netherlands, to manufacture estetrol in the early days of development. Output was enough for preclinical studies and Phase 1 clinical trials, but yields were low.
by Michael McCoy | June 27, 2021
The Swiss firm opened its first monoplant, for Clovis Oncology’s cancer drug rucaparib, in 2018. Aurinia’s monoplant is scheduled to open in 2023; until then, demand will be met from inventory. For Aurinia, a monoplant eliminates the inevitable wait for a manufacturing slot in a multipurpose plant.
by Vanessa Zainzinger, special to C&EN | June 27, 2021
/pharmaceuticals/oncology/BMS-pay-Eisai-650-million/99/i24 20210626 Concentrates 99 24 /magazine/99/09924.html BMS to pay Eisai $650 million for antibody-drug conjugate pharmaceuticals, oncology, antibody drug conjugate con bus Ryan Cross pharmaceuticals oncology business BMS will acquire Eisai ADC for cancer Chemical & Engineering News BMS to pay Eisai $650 million for antibody-drug conjugate BMS to pay Eisai $650 million for antibody-drug conjugate
by Ryan Cross | June 26, 2021
/biological-chemistry/cancer/X-rays-activate-cancer-drug/99/i24 20210626 Radiation removes molecular mask to free anticancer agent in mice, offering simultaneous chemotherapy and radiotherapy with fewer side effects Concentrates 99 24 /magazine/99/09924.html X-rays activate cancer drug prodrug, X-ray, doxorubicin, cancer, activate con scitech Mark Peplow, special to C&EN biological-chemistry cancer pharmaceuticals oncology X-rays trigger a rearrangement that removes the mask (red) from a doxorubicin prodrug.
by Mark Peplow, special to C&EN | June 26, 2021
/pharmaceuticals/oncology/RayzeBio-reaps-108-million-radiotherapies/99/i23 20210618 Concentrates 99 23 /magazine/99/09923.html RayzeBio reaps $108 million for radiotherapies oncology, pharmaceuticals, radiotherapy, rayzebio con bus Ryan Cross pharmaceuticals oncology business start-ups RayzeBio raises funds for radiotherapies Chemical & Engineering News RayzeBio reaps $108 million for radiotherapies RayzeBio reaps $108 million for radiotherapies
by Ryan Cross | June 18, 2021
Common wisdom in the field of oncology says that when a drug stops working it’s because tumor cells have mutated to evade it. But cancers have other sneaky ways of resisting our pharmacopeia, one of which is morphing into a state where they are vulnerable to a different kind of cell death. All of our current oncology drugs push tumors to their demise through a process called apoptosis, but some cancer cells alter their gene expression to become reliant on ferroptosis, explains Stuart Schreiber, cofounder of Kojin and a chemical biologist at Harvard University and Broad Institute of MIT and Harvard.
by Lisa M. Jarvis | June 09, 2021
The partners will use AI to accelerate the discovery of small-molecule drugs in areas including oncology and immunology. Kadmon, a New York City–based biotech firm, will use artificial intelligence supplied by Iktos for an undisclosed drug discovery program. Paris-based Iktos employs a structure-based modeling technique to identify compounds that match predefined target profiles.
May 22, 2021
Sterling Pharma Solutions will manufacture clinical quantities of a platinum-resistant oncology drug candidate for OncoTex. The British drug services firm will do the work at its Germantown, Wisconsin, plant, which specializes in high-potency active pharmaceutical ingredients. Evotec and Bristol Myers Squibb have launched a $20 million program called beLAB1407 to promote drug discovery at academic institutions in the UK.
May 15, 2021